Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05180162 · ClinicalTrials.gov registry record · Phase 1

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

A Phase 1 study of Pulmonary Fibrosis and Liver Fibrosis, sponsored by Thomas Hope.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT05180162 is a Phase 1 study of Pulmonary Fibrosis and Liver Fibrosis that has completed, run by Thomas Hope. The registered enrollment target is 16 participants, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05180162, a Phase 1 study of Pulmonary Fibrosis and Liver Fibrosis, has completed, sponsored by Thomas Hope.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.

Conditions Studied

Pulmonary Fibrosis Liver Fibrosis Myocardial Fibrosis

Interventions

  • DRUG 68Ga-FAP-2286
  • PROCEDURE Positron Emission Tomography (PET)

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2021-12-09
Est. Completion 2024-05-28
Phase Phase 1

Sponsor

Thomas Hope

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05180162

The ClinicalTrials.gov registry entry for NCT05180162 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (98% lower). The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which 68Ga-FAP-2286 is the first listed.

NCT05180162 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05180162 about?

NCT05180162 is a clinical study titled "Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286". This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP...

What is the current status of trial NCT05180162?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-12-09. Estimated completion is 2024-05-28.

What conditions does trial NCT05180162 study?

This clinical trial studies the following conditions: Pulmonary Fibrosis, Liver Fibrosis, Myocardial Fibrosis.

What interventions are being tested in trial NCT05180162?

The interventions under investigation include: 68Ga-FAP-2286 (DRUG), Positron Emission Tomography (PET) (PROCEDURE).

Who is sponsoring clinical trial NCT05180162?

This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05180162 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Fibrosis

All registered trials for this condition

Liver Fibrosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.